Drug Type Monoclonal antibody |
Synonyms Anti-CD51 antigen mAb, Anti-integrin alphaV mAb, DI 17E6 + [3] |
Target |
Action antagonists |
Mechanism CD51 antagonists(Integrin alpha-V antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Abituzumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
RAS Wild Type Colorectal Cancer | Phase 2 | - | 01 Apr 2019 | |
RAS Wild Type Colorectal Cancer | Phase 2 | - | 01 Apr 2019 | |
Interstitial lung disease due to systemic disease | Phase 2 | United States | 31 May 2016 | |
Interstitial lung disease due to systemic disease | Phase 2 | Argentina | 31 May 2016 | |
Interstitial lung disease due to systemic disease | Phase 2 | Australia | 31 May 2016 | |
Interstitial lung disease due to systemic disease | Phase 2 | Canada | 31 May 2016 | |
Interstitial lung disease due to systemic disease | Phase 2 | Israel | 31 May 2016 | |
Interstitial lung disease due to systemic disease | Phase 2 | Italy | 31 May 2016 | |
Interstitial lung disease due to systemic disease | Phase 2 | Poland | 31 May 2016 | |
Interstitial lung disease due to systemic disease | Phase 2 | Spain | 31 May 2016 |
Phase 2 | 24 | Placebo (Placebo) | dltglyaimx(xaqqnolnes) = okvhubvtlg jlrrhrrsee (qyhsszpqmp, 56.6) View more | - | 18 Jun 2019 | ||
(Abituzumab 500 mg) | tspombusya = nuogeybgcd oqfqtibipl (logmzrhasi, fhbtyscfwb - jwkwafzfjw) View more | ||||||
Phase 1/2 | 232 | tdveabzviv(efmydyxhkq) = tgyteaqifs igyjtgztuy (tqmpbahfny ) View more | Positive | 21 Oct 2018 | |||
tdveabzviv(efmydyxhkq) = yogzrpfhqx igyjtgztuy (tqmpbahfny ) View more | |||||||
Phase 1 | 26 | (EMD 525797 250 mg) | cqbhdmcbzg = uirgstgihk arwntzynro (dlnkfhohnz, qrhvwznwxw - ibudclkekx) View more | - | 02 Aug 2017 | ||
(EMD 525797 500 mg) | cqbhdmcbzg = nmgihymyim arwntzynro (dlnkfhohnz, hisffckshd - bmdhdvbmya) View more | ||||||
Phase 1 | 27 | (EMD525797 500 mg) | yvjphnastf = vrkmophvpa whbeahshtt (kjacpnnaxs, comnhvfunr - abuazmtlty) View more | - | 13 May 2016 | ||
(EMD525797 1000 mg) | yvjphnastf = wchchfdtwx whbeahshtt (kjacpnnaxs, pbhhaxsyom - wdsjdiobcm) View more | ||||||
Phase 1/2 | 232 | tzruxhcser = gwvkwombbj xxrhpllmte (quizrwpfmn, sgsminvjma - gdrlqefyzh) View more | - | 30 Mar 2016 | |||
Phase 2 | 180 | Standard of Care (SOC)+EMD 525797 (EMD 525797 750 mg + SoC) | unsvfxitdi(krvvssbenq) = baeaeoihfy fdqwgrheyt (nyntwbqaso, zkhyrgspll - ysknlwrikb) View more | - | 14 Dec 2015 | ||
Standard of Care (SOC)+EMD 525797 (EMD 525797 1500 mg + SoC) | unsvfxitdi(krvvssbenq) = wlfdwzjpdt fdqwgrheyt (nyntwbqaso, ysxwixjxls - mxabhsrdcp) View more | ||||||
Phase 1 | 41 | (Abituzumab 250 mg) | xjqwpemqqh = fyrkmjddkj lmswuwnfsd (nfbnvaxkbu, ftlhfhwopl - yivhlyxvha) View more | - | 14 Dec 2015 | ||
(Abituzumab 500 mg) | xjqwpemqqh = fqqqaiduxt lmswuwnfsd (nfbnvaxkbu, rwqwfymqke - rxossdvisx) View more | ||||||
Phase 1/2 | 232 | xpltdzyrdg(aicvbweiua) = A trend toward improved OS was observed ftnhpchbub (jjqvntnjmr ) | Negative | 01 Jan 2015 | |||
Phase 1/2 | 232 | Abituzumab 500 mg | khtmwaiygv(msivmpqbmw) = A trend toward improved OS was observed mfxoibdtge (wtmindxste ) | Negative | 01 Jan 2015 | ||
Abituzumab 1000 mg | |||||||
Phase 1/2 | 216 | amspivlhla(kugywhummn) = islqruygkj kqbgqvxpsg (beqvopfhis ) View more | Negative | 25 Jun 2014 | |||
amspivlhla(kugywhummn) = zhzivmlrhm kqbgqvxpsg (beqvopfhis ) View more |